# Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks

> **NCT05445557** · PHASE2 · COMPLETED · sponsor: **Raziel Therapeutics Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Flank Mass

## Interventions

- **DRUG:** RZL-012
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05445557
- **Lead sponsor:** Raziel Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-10
- **Primary completion:** 2022-10-20
- **Final completion:** 2022-11-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05445557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05445557, "Evaluation of Safety and Efficacy of RZL-012 in Subjects Seeking Fat Reduction in the Flanks". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05445557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*